Enjoy complimentary customisation on priority with our Enterprise License!
The gemcitabine hydrochloride market size is estimated to grow by USD 323.8 million at a CAGR of 7.08% between 2023 and 2028. The Gemcitabine Hydrochloride is experiencing significant growth due to the increasing cancer population worldwide. According to the World Health Organization, the number of new cancer cases is projected to reach 21.7 million by 2030. Additionally, there is a growing preference for chemotherapy drugs in developing countries as they offer effective treatment options for various types of cancer. The approval of new oncology drugs, such as immunotherapies and targeted therapies, is also fueling market growth. These innovative treatments offer improved efficacy and reduced side effects compared to traditional chemotherapy, making them increasingly popular among patients and healthcare providers. Overall, the oncology drugs market is poised for continued expansion due to these key drivers.
For More Highlights About this Report, Request Free Sample
Gemcitabine Hydrochloride is a synthetic pyrimidine nucleoside that acts as an anticancer drug. It is primarily used in the treatment of various types of cancers, including lung, cervical, breast, pancreatic, and prostate cancers, especially in the case of metastatic pancreatic cancer. Gemcitabine works by inhibiting DNA replication in cancer cells, thereby hindering tumor growth. Ipsen, a global specialty pharmaceutical company, is a significant player in the market. Its branded product, Onivyde, is a combination of Gemcitabine Hydrochloride and 5-FU, used in the treatment of metastatic pancreatic cancer. The increasing number of cancer cases worldwide, coupled with the growing pipeline analysis of Gemcitabine-based therapies, is expected to drive the market growth. Gemcitabine Hydrochloride is often used in combination with platinum agents or platinum doublet regimens to enhance its therapeutic effect. However, it may cause side effects such as myelosuppression, nausea, and fatigue. Despite these side effects, Gemcitabine Hydrochloride remains a crucial treatment option for various types of cancers. The National Library of Medicine provides critical information on various health topics, including cervical cancer, colon and rectum cancer, prostate cancer, the incidence of lung cancer among non-smoker population, FDA approved treatments like open angle glaucoma therapeutics, and management strategies for snake bites. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Increasing cancer population drive market growth is notably driving the market growth. Cancer is a major global health concern, with an estimated 1.80 million new cases diagnosed in the United States alone in 2020, resulting in approximately 606,520 related deaths (National Cancer Institute, 2021). The disease is caused by genetic changes that enable cells to grow and multiply uncontrollably, leading to the formation of tumors.
Furthermore, some of the most common types of cancer include lung, liver, stomach, colorectal, breast, and esophageal cancers. The increasing cancer population is a significant revenue pocket for the Gemcitabine Hydrochloride Market, as this drug is indicated for the treatment of various cancers, including pancreatic, ovarian, and bladder cancers. The primary route of administration for Gemcitabine Hydrochloride is intravenous infusion. The market for this drug is expected to grow due to the rising prevalence of cancer and the increasing demand for effective cancer treatments. Thus, such factors are driving the growth of the market during the forecast period.
Robust R&D activities fueling pipeline is the key trend in the market. The market is experiencing significant growth due to the increasing incidence of cancer and the resulting high unmet medical needs. According to a study published by the Multidisciplinary Digital Publishing Institute (MDPI) in 2019, the combination of gemcitabine hydrochloride with Danggui Buxue Tang (DBT) has shown enhanced inhibition effects on lung tumor growth.
Furthermore, this development, along with the expiry of patents for branded oncology products in June 2021, has led to substantial revenues for generic players in this market. The route of administration for gemcitabine hydrochloride is intravenous, making it an essential drug in the treatment of various cancers, including pancreatic, ovarian, and lung cancer. The indication for its use is extensive, making it a valuable asset in the oncology market. Thus, such trends will shape the growth of the market during the forecast period.
Growing popularity of alternate therapies for cancer in developed countries is the major challenge that affects the growth of the market. The market is witnessing significant growth due to its effectiveness in treating various indications, particularly cancer. However, the increasing trend towards alternate therapies, such as gene therapy and gene mutation technology, may hinder the market's growth prospects. This shift is driven by the need to target specific molecules responsible for cancer growth and the desire to minimize the side effects associated with chemotherapy drugs.
Furthermore, companies in the market are focusing on the development of biologic therapies, which offer higher specificity than traditional chemotherapy drugs. Despite this, chemotherapy drugs continue to be extensively researched to improve disease understanding and develop novel treatments. The Route of administration for Gemcitabine Hydrochloride is primarily intravenous, contributing significantly to its revenue pockets. Hence, the above factors will impede the growth of the market during the forecast period
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Apotex Inc. - The company offers gemcitabine hydrochloride that includes gemcitabine injection which is used for the treatment of lung cancer that has spread to other parts of the body and cannot be treated with surgery.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the generic segment will be significant during the forecast period. Gemcitabine Hydrochloride, a synthetic pyrimidine nucleoside antimetaboliteantineoplastic agent, is primarily used in the treatment of various types of cancer, including lung, cervical, breast, pancreatic, and prostate cancers, particularly in metastatic pancreatic cancer and squamous cell lung cancer. The Lung Cancer Foundation, in collaboration with Ipsen, the manufacturer, has been advocating for the use of Gemcitabine Hydrochloride under the brand name Onivyde.
Get a glance at the market share of various regions Download the PDF Sample
The generic segment showed a gradual increase in the market share of USD 412.90 million in 2018. This anticancer drug works by inhibiting DNA replication and promoting apoptosis, leading to tumor growth suppression. The prevalence of cancer continues to rise, with an estimated 1.9 million new cancer cases and 600,000 cancer deaths in the US in 2020. Product developments and clinical trials in the oncology sector have led to new treatment options for patients, including Gemcitabine Hydrochloride. Ipsen's Gemcitabine Hydrochloride is FDA-approved for treating pancreatic cancer and is often used in combination with platinum agents as part of platinum doublet regimens. Patient support programs and regulatory frameworks play a crucial role in ensuring access to this essential treatment. The non-smoker and female populations are particularly vulnerable to certain types of cancer, such as lung and breast cancer, respectively. Side effects of Gemcitabine Hydrochloride include nausea, fatigue, and neutropenia. The drug is available through healthcare professionals, retail pharmacies, and digital channels for both domestic and localized use. In the pipeline analysis, Gemcitabine Hydrochloride continues to be a significant player in the fight against cancer.
For more insights on the market share of various regions Download PDF Sample now!
Asia is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Gemcitabine Hydrochloride, a synthetic pyrimidine nucleoside, is a vital antimetabolite antineoplastic agent used in the treatment of various types of cancer, including lung, cervical, breast, pancreatic, and prostate cancers. The Lung Cancer Foundation, in collaboration with Ipsen, has been instrumental in the development and approval of Onivyde, a gemcitabine hydrochloride-based treatment, for metastatic squamous cell lung cancer and small lung cancer. This anticancer drug works by inhibiting DNA replication and promoting apoptosis (programmed cell death), thereby impeding tumor growth. The prevalence of cancer continues to rise, with an estimated 1.9 million new cases and 608,570 deaths in the US alone in 2020. As a result, the demand for effective treatment options, such as gemcitabine hydrochloride, is increasing. Ipsen's Onivyde is also approved for the treatment of metastatic pancreatic cancer in combination with a platinum agent, expanding the therapeutic possibilities for patients. Clinical trials and product developments are ongoing to explore the potential of gemcitabine hydrochloride in treating other cancer types, such as breast and prostate cancers. Patient support programs and the regulatory framework play a crucial role in ensuring access to these treatments for the growing cancer patient population, including the non-smoker and female populations. Side effects associated with gemcitabine hydrochloride include myelosuppression, nausea, and fatigue. Healthcare professionals and retail pharmacies play a significant role in managing these side effects and providing domestic and localized treatment options through digital channels. The FDA has approved gemcitabine hydrocloride under the brand name Gemzar for various indications, making it an essential oncology agent in the fight against cancer.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million " for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
Biotechnology Reagents Market: Analysis North America, Europe, Asia, Rest of World (ROW) - US, China, Germany, France, Japan - Size and Forecast
Genomics Market: Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, Germany, France, China - Size and Forecast
Montelukast Sodium Market: by Type and Geography - Forecast and Analysis
Gemcitabine Hydrochloride is a synthetic pyrimidine nucleoside antimetaboliteantineoplastic agent that plays a significant role in cancer treatment. Ipsen, a global specialty pharmaceutical company, markets Gemcitabine Hydrochloride under the brand name Onivyde. It is used for the treatment of various types of cancers, including pancreatic, cervical, breast, lung (Squamous cell and Small lung), and prostate cancers, as well as metastatic pancreatic cancer. The prevalence of cancer continues to rise, with an estimated 19.3 million new cases and 10.0 million deaths in 2020. The increasing number of cancer cases and the need for effective treatment options have driven the market. Clinical trials and product developments are ongoing to expand the use of Gemcitabine Hydrochloride in cancer treatment. For instance, Ipsen is conducting clinical trials to evaluate the efficacy of Gemcitabine Hydrochloride in combination with other oncology agents for various cancer indications.
Furthermore, the regulatory framework for Gemcitabine Hydrochloride is well-established, with the FDA approving it for various indications under the brand name Gemzar. The drug is administered intravenously and works by inhibiting DNA replication and promoting apoptosis (programmed cell death). The market is influenced by the non-smoker and female population, as they are at a higher risk of developing certain types of cancer. The market is also driven by patient support programs and the availability of the drug through retail pharmacies and digital channels. Side effects associated with Gemcitabine Hydrochloride include nausea, vomiting, and neutropenia. The drug is typically used in combination with platinum agents or platinum doublet regimens to enhance its efficacy. Pipeline analysis suggests that several companies are developing Gemcitabine Hydrochloride for various indications, making the market competitive. The market is expected to grow significantly due to the increasing number of cancer cases and the need for effective treatment options.
Market Scope |
|
Report Coverage |
Details |
Page number |
132 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.08% |
Market growth 2024-2028 |
USD 323.8 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
6.49 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
Asia at 36% |
Key countries |
US, Germany, Canada, China, and UK |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Apotex Inc., Biocon Ltd., Cipla Inc., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Emcure Pharmaceuticals Ltd., Fresenius Kabi AG, Ingenus Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Lianyungang Jinkang Pharmaceutical Technology Co. Ltd., Merck KGaA, Nichi Iko Pharmaceutical Co. Ltd., Pfizer Inc., Shilpa Medicare Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd. |
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.